Management of Patients with Relapsed and/or Refractory Multiple Myeloma

Management of Patients With Relapsed and/or Refractory Multiple Myeloma

Elsevier CME Independent Conference Highlights of the ASH 2017* Annual Meeting

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on the management of patients with relapsed and/or refractory multiple myeloma. During the virtual roundtable discussion, 3 experts summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology Association (ASH) 2017 Annual Meeting.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of a broad audience including oncologists, hematologists, pathologists, pediatricians, and other healthcare professionals (HCPs) responsible for the diagnosis, treatment, or management of patients with relapsed and/or refractory multiple myeloma.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to:

  1. Understand the changing treatment paradigm for relapsed and/or refractory multiple myeloma and the balance between high quality responses and quality of life
  2. Analyze the latest clinical trial data available for the treatment of relapsed and/or refractory multiple myeloma with current, novel, and emerging therapies
  3. Identify and optimally select which relapsed and/or refractory multiple myeloma patients are eligible for current or novel treatment strategies

FACULTY

Keith Stewart, MB, ChB
Mayo Clinic
Phoenix, AZ and Rochester, MN, USA

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Sagar Lonial, MD, FACP
Winship Cancer Institute
Atlanta, GA, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Keith Stewart, MB, ChBConsultant/Advisor: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Global Services, LLC
Paul Richardson, MDConsultant/Advisor: Celgene Corporation, Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited
Sagar Lonial, MD, FACPConsultant/Advisor: Amgen Inc. , Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Limited

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Cordelia Nagle; Megan Cannon, PhD; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Amgen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
06/21/2018
Course expires: 
06/20/2019
Rating: 
5

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
06/21/2018
Course expires: 
06/20/2019
Please login or register to take this course.